Skip to main content

Table 1 Susceptibility pattern of nosocomial infection agents obtained at local and central laboratories.

From: Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study

Drugs % Susceptibility (Number tested)
  Locally determined Centralized
  Routine Etest Agar DM
Escherichia coli
Meropenem 100 (92) 100 (139) 100 (139)
Imipenem 100 (139) 100 (139) 100 (139)
Piperacillin/tazobactam* 82 (139) 89 (139) 90 (139)
Enterobacteriaceae (other than E coli)
Meropenem 100 (86) 99 (139) 99 (139)
Imipenem 99 (139) 97 (139) 97 (139)
Piperacillin/tazobactam* 78 (139) 86 (139) 99 (139)
Pseudomonas aeruginosa
Meropenem 87 (87) 91 (129) 95 (129)
Imipenem 78 (137) 70 (129) 84 (129)
Piperacillin/tazobactam* 88 (136) 89 (129) 90 (129)
Acinetobacter
Meropenem 88 (50) 87 (86) 95 (79)
Imipenem 94 (84) 94 (86) 97 (79)
Piperacillin/tazobactam* 79 (82) 80 (86) 100* (79)
Other non fermentative bacteria
Meropenem 73 (33) 89 (33) 88 (33)
Imipenem 85 (41) 87 (33) 88 (33)
Piperacillin/tazobactam* 90 (41) 97 (33) 90 (33)
Staphylococcus aureus (susceptible to methicillin)
Meropenem - 100 (145) 100 (145)
Imipenem - 100 (145) 100 (145)
Piperacillin/tazobactam* - 100 (145) 100 (145)
Coagulase negative staphylococci (susceptible to methicillin)
Meropenem - 100 (129) 100 (129)
Imipenem - 100 (129) 100 (129)
Piperacillin/tazobactam* - 100 (129) 100 (129)
Streptococcus pneumoniae
Meropenem - 100 (136) 100 (136)
Imipenem - 100 (136) 100 (136)
Piperacillin/tazobactam* - 100 (136) 100 (136)
  1. *Tazobactam: 4 mg/L